Chandra Belani

Trials

Studies that name Chandra Belani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:11 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT00887159 · A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

  National Cancer Institute (NCI) · completed · Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma · principal investigator
• Ph2
  NCT00481078 · Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

  National Cancer Institute (NCI) · completed · Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · principal investigator
• Ph2
  NCT00372073 · Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

  Cyclacel Pharmaceuticals, Inc. · terminated · Non-small Cell Lung Cancer · study chair
• Ph2
  NCT00251498 · Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

  Veeda Oncology · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
• Ph1
  NCT00089271 · 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

  National Cancer Institute (NCI) · completed · Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• CLINICAL TRIAL: PI & PHARMACOKINETIC STUDY OF DRUG FOR SOLID TUMORS & LYMPHOMAS
  M01RR010732 · NCRR · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · fiscal years 2009 · $925 awarded in 2009
  Same name and institution; not confirmed by an ID
• Phase I Clinical Trials of Novel Anticancer Agents
  U01CA099168 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2003 to 2006 · $428,535 awarded in 2006
  Grant number is on one of their registry trials
• PHASE I PHARMACOKINETIC STUDY OF CARBOPLATIN IN COMBO WITH WEEKLY PACLITAXEL
  M01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 1996 to 2000 · $3,034 awarded in 2000
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
  Named on NCT00887159
• Eastern Cooperative Oncology Group Operations Office
  U10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013
  Named on NCT00887159
• Phase I Clinical Trials of Anticancer Agents
  U01CA069912 · NCI · MAYO CLINIC ROCHESTER · PI CHARLES ERLICHMAN · fiscal years 1995 to 2013
  Named on NCT00089271
• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062502 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AFSHIN DOWLATI · fiscal years 1994 to 2013
  Named on NCT00089271